Fintel reports that on January 30, 2025, Stephens & Co. downgraded their outlook for Paragon 28 (NYSE:FNA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 12.29% Upside As of January ...

Joining Zimmer Biomet is an exciting new chapter for Paragon 28 and an incredible opportunity to advance our mission and contin ...

Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire Paragon 28.

Piper Sandler & Co. is serving as exclusive financial advisor to Paragon 28 and Cravath, Swaine & Moore LLP is serving as legal advisor. Zimmer Biomet is a global medical technology leader with ...

Zimmer Biomet to buy medical device company, Paragon 28 for $1.2 billion: Warsaw, Indiana Thursday, January 30, 2025, 14:00 Hrs [IST] Zimmer Biomet Holdings, Inc., a global medica ...

Several hedge funds have recently modified their holdings of FNA. JPMorgan Chase & Co. raised its position in Paragon 28 by 2,141.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 784,878 ...

During the last three months, 5 analysts shared their evaluations of Paragon 28 (NYSE:FNA), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

Paragon 28, Inc. (NYSE:FNA – Get Free Report) has earned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Ratings reports. Four research analysts have ...

Expedites penetration opportunities in the fast-growing ASC space.

Piper Sandler & Co is to provide exclusive financial advisory services for Paragon 28 while Cravath, Swaine & Moore will act as its legal advisers. Last month, Zimmer Biomet received 510(k ...

Since its inception, Paragon 28 has been singularly focused on bringing to market innovative solutions to address areas of unmet need in the foot and ankle segment. Strengthens and expands ...